Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1977 1
1980 2
1981 1
1982 2
1984 1
1985 5
1986 3
1987 2
1988 8
1989 6
1990 6
1991 12
1992 5
1993 6
1994 11
1995 9
1996 13
1997 6
1998 9
1999 8
2000 10
2001 11
2002 18
2003 16
2004 14
2005 13
2006 17
2007 17
2008 26
2009 30
2010 28
2011 31
2012 51
2013 47
2014 45
2015 47
2016 61
2017 49
2018 60
2019 64
2020 81
2021 69
2022 67
2023 74
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

942 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Increased risk for multiple myeloma"
Page 1
Multiple myeloma.
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Kumar SK, et al. Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46. Nat Rev Dis Primers. 2017. PMID: 28726797 Review.
Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of undetermined significance and smouldering multiple myeloma is important, as observation is the standard for those condition …
Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of unde …
Prognostic and predictive biomarker developments in multiple myeloma.
Wallington-Beddoe CT, Mynott RL. Wallington-Beddoe CT, et al. J Hematol Oncol. 2021 Sep 23;14(1):151. doi: 10.1186/s13045-021-01162-7. J Hematol Oncol. 2021. PMID: 34556161 Free PMC article. Review.
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease characteristics …
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, …
Bortezomib for the treatment of multiple myeloma.
Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Scott K, et al. Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD010816. doi: 10.1002/14651858.CD010816.pub2. Cochrane Database Syst Rev. 2016. PMID: 27096326 Free PMC article. Review.
BACKGROUND: Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. ...There is high-quality evidence for increased risk of cardiac disorders from analysing trials of bortezomi …
BACKGROUND: Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematologi …
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. Mateos MV, et al. Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3. Blood Cancer J. 2020. PMID: 33067414 Free PMC article.
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). ...This translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% …
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). ...This translate …
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS; Non-communicable Disease Global Health Research Group, Association of Pacific Rim Universities. Huang J, et al. Lancet Haematol. 2022 Sep;9(9):e670-e677. doi: 10.1016/S2352-3026(22)00165-X. Epub 2022 Jul 14. Lancet Haematol. 2022. PMID: 35843248
BACKGROUND: Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple myeloma in 2020. ...The overall decreasing global trend of multiple myeloma mortality was more evident in women. L …
BACKGROUND: Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple …
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF. Sanfilippo KM, et al. Am J Hematol. 2019 Nov;94(11):1176-1184. doi: 10.1002/ajh.25603. Epub 2019 Aug 19. Am J Hematol. 2019. PMID: 31379000 Free PMC article.
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-ri …
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The Inter …
Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016.
Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, Wang L; Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology; Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology. Liu J, et al. J Hematol Oncol. 2019 Dec 10;12(1):136. doi: 10.1186/s13045-019-0807-5. J Hematol Oncol. 2019. PMID: 31823802 Free PMC article.
BACKGROUND: The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China. ...RESULTS: It was estimated that there were 16,500 new cases and 10,300 deaths of multiple myeloma in China in 2016. …
BACKGROUND: The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in …
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, Cho HJ, Parekh SS, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez LJ, Thibaud S, Jagannath S, Chari A. Lancman G, et al. Blood Cancer Discov. 2023 Nov 1;4(6):440-451. doi: 10.1158/2643-3230.BCD-23-0049. Blood Cancer Discov. 2023. PMID: 37769148 Free PMC article.
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. ...SIGNIFICANCE: To the best of our knowledge, this is the first study to comprehensively analyze …
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infection …
Conditional survival in multiple myeloma and impact of prognostic factors over time.
Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Abdallah NH, et al. Blood Cancer J. 2023 May 15;13(1):78. doi: 10.1038/s41408-023-00852-4. Blood Cancer J. 2023. PMID: 37188699 Free PMC article.
Overall survival estimates from diagnosis are valuable for guiding treatment, but do not consider the years already survived. Conditional survival (CS) provides dynamic survival predictions over time. This study was conducted to estimate CS at 1-8 years from diagnosis and …
Overall survival estimates from diagnosis are valuable for guiding treatment, but do not consider the years already survived. Conditional su …
Genome instability in multiple myeloma.
Neuse CJ, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M, Ghobrial IM. Neuse CJ, et al. Leukemia. 2020 Nov;34(11):2887-2897. doi: 10.1038/s41375-020-0921-y. Epub 2020 Jul 10. Leukemia. 2020. PMID: 32651540 Review.
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. ...We suggest that assessing CIN in MM and its precursors states may help improve predicting the risk …
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heter …
942 results